Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 151 - 200 av 206 resultater
Tid
Selskap
Tittel
Sektor
Kategori
28 Apr 2022
18:17 CEST
ABIONYX PHARMA
ABIONYX Pharma : Résultats annuels 2021
20103010 Biotechnology
Other subject
07 Apr 2022
07:30 CEST
ABIONYX PHARMA
ABIONYX Pharma Reports Positive Interim Results From Phase 2a Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury
20103010 Biotechnology
Other subject
07 Apr 2022
07:30 CEST
ABIONYX PHARMA
ABIONYX Pharma annonce des résultats intermédiaires positifs dans l'essai clinique de phase 2a évaluant CER-001 dans le traitement des patients atteints de septicémie à haut risque de développer une lésion rénale aiguë
20103010 Biotechnology
Other subject
04 Apr 2022
17:45 CEST
ABIONYX PHARMA
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
04 Apr 2022
17:45 CEST
ABIONYX PHARMA
ABIONYX Pharma : Information relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
29 Mar 2022
18:34 CEST
ABIONYX PHARMA
ABIONYX Pharma annonce que la Food and Drug Administration (FDA) a accordé la désignation de médicament orphelin (ODD) au CER-001 pour le traitement du déficit en LCAT, dans la dysfonction rénale et/ou la maladie ophtalmologique
20103010 Biotechnology
Other subject
29 Mar 2022
18:34 CEST
ABIONYX PHARMA
ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease
20103010 Biotechnology
Other subject
24 Mar 2022
18:43 CET
ABIONYX PHARMA
ABIONYX Pharma annonce des résultats cliniques positifs pour CER-001 dans le traitement de la COVID-19, publiés dans la revue Biomedecines, démontrant que CER-001 limite les effets de l’inflammation
20103010 Biotechnology
Other subject
24 Mar 2022
18:43 CET
ABIONYX PHARMA
ABIONYX Announces Positive Clinical Findings for CER-001 in Treating COVID-19, Published in Biomedecines, Demonstrating That CER-001 Limits Inflammation Effects
20103010 Biotechnology
Other subject
04 Mar 2022
17:45 CET
ABIONYX PHARMA
ABIONYX Pharma : Information relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
04 Mar 2022
17:45 CET
ABIONYX PHARMA
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
24 Feb 2022
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma fait le point sur son activité et sa position de trésorerie du 4e trimestre 2021
20103010 Biotechnology
Other subject
24 Feb 2022
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma Provides an Update on Its Business and Cash Position for Q4 2021
20103010 Biotechnology
Other subject
07 Feb 2022
18:53 CET
ABIONYX PHARMA
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
07 Feb 2022
18:53 CET
ABIONYX PHARMA
ABIONYX Pharma : Information relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
31 Jan 2022
17:45 CET
ABIONYX PHARMA
ABIONYX Pharma Announces Its Financial Agenda for the Year 2022
20103010 Biotechnology
Other subject
31 Jan 2022
17:45 CET
ABIONYX PHARMA
ABIONYX Pharma annonce son calendrier de communication financière pour l’exercice 2022
20103010 Biotechnology
Other subject
05 Jan 2022
17:45 CET
ABIONYX PHARMA
ABIONYX Pharma : Information relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
05 Jan 2022
17:45 CET
ABIONYX PHARMA
ABIONYX Pharma : Bilan semestriel S2 du contrat de liquidité contracté avec la Société TP ICAP (Europe) SA
20103010 Biotechnology
Other subject
05 Jan 2022
17:45 CET
ABIONYX PHARMA
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
03 Jan 2022
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma Announces That the French Drug Safety Agency (Agence Nationale de Sécurité du Médicament or ANSM) Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease
20103010 Biotechnology
Other subject
03 Jan 2022
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma a reçu une Autorisation d'Accès Compassionnel par l’ANSM pour sa bio-HDL (CER-001) dans la COVID-19
20103010 Biotechnology
Other subject
06 Dec 2021
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
06 Dec 2021
18:00 CET
ABIONYX PHARMA
ABIONYX Pharma : Information relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
06 Dec 2021
07:30 CET
ABIONYX PHARMA
ABIONYX Pharma Announces the Completion of a Contribution in Kind to the Company of 100% of the Capital of IRIS Pharma Holding, Fully Compensated by the Issue of New Shares at a Price of €3.60 Per Share to Become a Specialist of Bioproducts...
20103010 Biotechnology
Other subject
06 Dec 2021
07:30 CET
ABIONYX PHARMA
ABIONYX Pharma annonce la réalisation définitive de l’apport en nature de titres Iris Pharma holding rémunéré par la remise d’actions ABIONYX Pharma au prix de 3,60€ pour devenir un spécialiste des biomédicaments en ophtalmologie...
20103010 Biotechnology
Other subject
02 Dec 2021
07:36 CET
ABIONYX PHARMA
ABIONYX Announces the Success of Its Capital Increase in Cash by Private Placement at a Price of €3.60 Per Share
20103010 Biotechnology
Other subject
02 Dec 2021
07:36 CET
ABIONYX PHARMA
ABIONYX annonce le succès de son augmentation de capital en numéraire par placement privé au prix de 3,60€ par action
20103010 Biotechnology
Other subject
17 Nov 2021
19:51 CET
ABIONYX PHARMA
ABIONYX Announces the Signing of an Agreement for the Contribution of 100% of the Capital of IRIS Pharma Holding, Fully Remunerated by the Issuance of New ABIONYX Shares at a Fixed Price of 3.60 Euros per Share
20103010 Biotechnology
Other subject
17 Nov 2021
19:51 CET
ABIONYX PHARMA
ABIONYX annonce la signature d’un accord portant sur l’apport de 100% du capital d’IRIS Pharma Holding rémunéré entièrement par l’émission d’actions nouvelles ABIONYX au prix fixé de 3,60 euros par action
20103010 Biotechnology
Other subject
15 Nov 2021
07:30 CET
ABIONYX PHARMA
ABIONYX Pharma annonce de nouveaux résultats cliniques positifs pour CER-001 dans les maladies rénales associées à un déficit en LCAT publiés dans la revue « Journal of Internal Medicine »
20103010 Biotechnology
Other subject
15 Nov 2021
07:30 CET
ABIONYX PHARMA
ABIONYX Announces New Positive Clinical Results for CER-001 in kidney disease associated with LCAT deficiency Published in The Journal of Internal Medicine
20103010 Biotechnology
Other subject
08 Nov 2021
19:00 CET
ABIONYX PHARMA
ABIONYX Pharma : Information relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
08 Nov 2021
19:00 CET
ABIONYX PHARMA
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
04 Nov 2021
18:45 CET
ABIONYX PHARMA
ABIONYX Pharma annonce sa position de trésorerie et fait le point sur l’activité du 3ème trimestre 2021
20103010 Biotechnology
Other subject
04 Nov 2021
18:45 CET
ABIONYX PHARMA
ABIONYX Pharma Announces Its Cash Position and Provides an Activity Update for the 3rd Quarter 2021
20103010 Biotechnology
Other subject
11 Oct 2021
19:11 CEST
ABIONYX PHARMA
ABIONYX Pharma Initiates Discussions With IRIS Pharma, a World Leader in Preclinical and Clinical Ophthalmology Research, With a View to a Possible Strategic Deal
20103010 Biotechnology
New
11 Oct 2021
19:11 CEST
ABIONYX PHARMA
ABIONYX Pharma initie des échanges avec la société IRIS Pharma, l’un des leaders mondiaux de la recherche préclinique et clinique en ophtalmologie, en vue d’un éventuel rapprochement stratégique
20103010 Biotechnology
New
07 Oct 2021
08:46 CEST
ABIONYX PHARMA
ABIONYX Pharma Announces Positive Preclinical Results in a Model of Uveitis and Launches the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its bio-HDL
20103010 Biotechnology
New
07 Oct 2021
08:46 CEST
ABIONYX PHARMA
ABIONYX Pharma annonce des résultats précliniques positifs dans un modèle d’uvéite et lance le développement stratégique de la première classe de biomédicaments en ophtalmologie à partir de sa bio-HDL
20103010 Biotechnology
New
05 Oct 2021
18:00 CEST
ABIONYX PHARMA
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
05 Oct 2021
18:00 CEST
ABIONYX PHARMA
ABIONYX Pharma : Information relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
09 Sep 2021
19:10 CEST
ABIONYX PHARMA
ABIONYX Pharma : Mise à disposition du rapport financier semestriel 2021
20103010 Biotechnology
Other subject
09 Sep 2021
18:55 CEST
ABIONYX PHARMA
ABIONYX Pharma annonce ses résultats financiers du 1er semestre 2021 et fait le point sur le développement de ses activités
20103010 Biotechnology
Income
09 Sep 2021
18:55 CEST
ABIONYX PHARMA
ABIONYX Pharma Announces Its 2021 Half Year Financial Results and Provides an Update on Its Development Activities
20103010 Biotechnology
Income
03 Sep 2021
17:45 CEST
ABIONYX PHARMA
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
03 Sep 2021
17:45 CEST
ABIONYX PHARMA
ABIONYX Pharma : Information relative au nombre total de droits de vote et d’actions composant le capital social
20103010 Biotechnology
Other subject
05 Aug 2021
19:26 CEST
ABIONYX PHARMA
ABIONYX Pharma: Gross Cash Position and Business Update for the First Half Of 2021
20103010 Biotechnology
Other subject
05 Aug 2021
19:26 CEST
ABIONYX PHARMA
ABIONYX Pharma : Position de trésorerie brute et point sur l’activité du 1er semestre 2021
20103010 Biotechnology
Other subject
03 Aug 2021
17:45 CEST
ABIONYX PHARMA
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
20103010 Biotechnology
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
3
4
5
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva